Editorial Commentary
Management of acquired resistance to ALK inhibitors: repeat biopsy to characterize mechanisms of resistance significantly impacts clinical outcomes
Precision Cancer Medicine
2021;
4:
20
.
(30 June 2021)
Editorial Commentary
PARP inhibitors beyond BRCA-mutated cancers: precision medicine at the crossroads
Precision Cancer Medicine
2021;
4:
19
.
(30 June 2021)
Editorial Commentary
Lung cancer screening: think pink!
Precision Cancer Medicine
2021;
4:
18
.
(30 June 2021)
Case Report
Effectiveness of pemetrexed-based chemotherapy and radiation therapy in RET-rearranged lung adenocarcinoma: a mono-institutional case series
Precision Cancer Medicine
2021;
4:
17
.
(30 June 2021)
Review Article
ROS-1 NSCLC therapy resistance mechanism
Precision Cancer Medicine
2021;
4:
16
.
(30 June 2021)
Review Article
Monitoring therapeutic response and resistance with liquid biopsy
Precision Cancer Medicine
2021;
4:
15
.
(30 June 2021)
Review Article
Non-small cell lung cancer molecular characterization of advanced disease with focus on sex differences: a narrative review
Precision Cancer Medicine
2021;
4:
14
.
(30 June 2021)
Review Article
A narrative review of chemotherapy in advanced triple negative breast cancer
Precision Cancer Medicine
2021;
4:
13
.
(30 June 2021)
Review Article
Triple negative breast cancer: emerging light on the horizon—a narrative review
Precision Cancer Medicine
2021;
4:
12
.
(30 June 2021)
Original Article
The use of stereotactic body radiotherapy in pulmonary carcinoid tumors: a case series
Precision Cancer Medicine
2021;
4:
11
.
(30 June 2021)